Introduction: Current succesful AGC (Accurate Glycemic Control) protocols require extra clinical effort and are impractical in less acute wards where patients are still susceptible to stress-induced hyperglycemia. Long-acting insulin Glargine has the potential to be used in a low effort controller. However, potential variability in efficacy and length of action, prevent direct in-hospital use in an AGC framework for less acute wards.
Introduction
Critically ill patients often suffer stress induced hyperglycemia [1] . Hyperglycemia is associated with an increased risk of infection, myocardial infarction and mortality [2] [3] [4] .
Attempting to control hyperglycemia can significantly increase the risk of hypoglycemia [5] making original promising results [6, 7] difficult to repeat [8] [9] [10] . The SPRINT glycemic control protocol [7] is the only published protocol to reduce both mortality and hypoglycemia. However, it requires BG measurements every 1 -2 hours. Thus, the clinical effort required is high and may not be necessary for all patients.
It is common for patients to be admitted to a High Dependency Unit (HDU) if they are not intubated or do not require extensive circulatory support. There can be a reluctance to use AGC (Accurate Glycemic Control) protocols in the HDU due to the clinical effort and relatively limited nursing resources [11] , leading to a tolerance of some hyperglycemia.
However, these patients are still susceptible to counter-regulatory stress responses and hyperglycemia, necessitating an effective method to transition glycemic control from critical care to less acute wards with less nursing resources and less use of intravenous lines to deliver insulin or other drugs.
Glargine is a very long acting insulin analogue used to manage Type 1 diabetes, primarily in relatively low doses (per hour) to replace basal insulin. It is administered subcutaneously and released very slowly into the blood plasma over 22 -26 hours [12] . Hence, it has potential advantages for a low intensity AGC protocol requiring only one daily administration.
Although many studies have been carried out on the specific kinetics and dynamics of Glargine in healthy individuals, there is still insufficient data for use with in-hospital AGC protocols on highly dynamic, critically ill patients. Current studies indicate that Glargine may be up to twice as potent as regular insulin [13] , which, with varying kinetics and appearance rates [14] , could add significant risk in using higher doses for these patients whose insulin sensitivity can vary significantly over time compared to healthy individuals [15] .
Further clinical information about the dynamics of Glargine in these patients is required to avoid unnecessary risk. Model-based control and simulation environments can be used to develop clinical protocols to safely examine different expected action profiles and efficacy of Glargine in these patients, while simultaneously providing AGC. In particular, this study develops a first model-based controller to be used in 24 hour pilot trials to assess the potential of Glargine in this cohort, and to also collect data on the issues of efficacy and kinetics while producing safe, effective AGC in a replicable fashion. This is the first example to employ model-based control to elucidate specific drug properties.
Methods:
The SING (Stochastic Insulin Nutrition and Glargine) controller was developed using clinically validated virtual trials [16] on virtual patients based on retrospective clinical data. It combines the ICING (Intensive Control Insulin Nutrition Glucose) model [17] of insulinglucose pharmacokinetics and pharmacodynamics and glucose disappearance in plasma with a validated model of subcutaneous pharmacokinetics of Glargine from injection to appearance in plasma [18] [19] [20] and makes use of the stochastic forecasting used in STAR [21] .
ICING Model:
Five differential equations describe the glucose-insulin pharmacokinetics and pharmacodynamics in the plasma and interstitium with one state-dependent function: [mmol] represents glucose in the gut. Enteral glucose input is denoted P(t) [mmol/min]. Table 1 shows the major components and constants of the model defined in Equations 1-5. A graphical overview is presented in Figure 1 . 
Glargine Compartment Model
The Glargine Compartment model captures the kinetics of Glargine from injection to appearance in plasma. Glargine has four states: precipitate, hexameric, monomeric / dimeric, and local interstitium. Figure 2 shows the interaction of these states [18, 19] . The resulting compartment model is defined:
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Interstitium (t) in the hexameric form. All other terms and values are defined in Table 2 , based on an extensive validation study [18, 19] . 
where r [cm] is the radius of the depot formed by the subcutaneous injection and D [cm 2 /min] is the diffusion constant for the hexameric and monomeric /dimeric states.
Finally the initial quantity of the Dimeric/Monomeric state in solution is found by solving the following derived from [19] :
Control Approach
The main goal is to develop a robust and safe controller to investigate the efficacy and variability in Glargine kinetics, without degrading control quality or safety from hypoglycemia. The main issues are the potential variation in Glargine efficacy (1.0-2.0x), the periods of low insulin appearance at the start and end of Glargine's 22-26 hour action period, and the need to modulate nutrition rates during Glargine administration for safety and performance because insulin administration is determined solely by Glargine appearance.
There is evidence suggesting that Glargine may be to be up to 2 times as effective as regular insulin, partly attributed to a more effective bonding to the IGF-I receptor [22] . Hence, this study assumes an estimated Glargine efficacy factor of 1.5 for design, in the absence of other data. Each resulting controller was then tested with efficacy factors of 1.0, 1.5 and 2.0. If a controller provided a satisfactory level of control for all three efficacies then it was deemed safe and robust to this variable.
Although Glargine has a relatively flat action profile that acts over a 22-26 hour period [23] , 3-6 hours is required before a significant appearance of insulin is observed in plasma, resulting in a period of low insulin appearance immediately after Glargine is administered. A similar phenomenon occurs at the end of the 22-26 hour period. For this trial design, the STAR protocol [21] is assumed running during the first and last 4 or 6 hours of the estimated 24-hour period after Glargine is administered to supplement Glargine appearance with IV insulin, as it is the current standard of care in Christchurch Hospital.
To best observe the effects of Glargine, a period of Glargine as the only exogenous insulin is desired to eliminate other factors. However, longer periods increase the potential for control degradation. During the 16-hour peak of Glargine action, no exogenous insulin is administered, during which glycemic control is achieved only by modulating nutrition administration rates. The results will allow determination of Glargine efficacy and kinetics for each patient, and thus their variability across a test cohort.
BG measurements are intended to be taken hourly during the 24-hour trials to ensure safety.
However, for in-silico virtual trials, 2 and 3-hourly BG measurements are used for the Glargine isolation period to illustrate the potential to reduce clinical effort.
Glargine bolus size was based on the total insulin previously administered to the patient, as a simple and easily calculated bedside metric. The sum over the previous 12, 18 and 24 hours before the Glargine is administered was tested. Values less than the 24-hour sum reflect both safety concerns over efficacy, as well as the tendency for stable patients to improve and require increasingly less insulin [15] . The clinical trial design consists of:
• Glargine administered based on patient's previous insulin requirements
• STAR recommended insulin boluses administered on top of the Glargine at the start and end of the action profile. The 5 th percentile BG outcome to low bound target is used in this period.
• No exogenous IV insulin is recommended during the 16-hour peak Glargine appearance, 95 th percentile BG outcome to high bound target is used.
• BG measurements hourly for safety
Finally, a second controller, SING2, is designed specifically to demonstrate the potential reductions in effort if the efficacy of Glargine is known so that a more aggressive and lower clinical effort control method can be implemented safely. The SING2 controller's logic in this specific case is defined:
• Assumes Glargine efficacy of 1.5x
• Glargine bolus size equal to the insulin administered over the previous 24 hours
• STAR recommended boluses on top of Glargine for all 24-hours • 2 and 3 hourly treatments permitted per STAR [21] • 95 th percentile BG outcome is targeted to the high bound
• The upper tolerance band on the upper target is 1 mmol/L
Virtual Trials
Clinically validated virtual trials [16] were run on virtual patients made from retrospective clinical data. The virtual patients were created using the clinical data to create hourly insulin sensitivity profiles which are used to simulate the effects of different treatments on the patients.
The following virtual trials were run on the virtual patient cohort. Simulation outcomes for the 24 hour trials were used to verify performance both directly against SPRINT.
• Glargine bolus size equal to total insulin recommendations over the previous 12, The outcomes are used to determine the most robust and safest dose and control response.
Performance Metrics
Results from the clinically validated in-silico virtual trials are compared to the original SPRINT clinical data to assess safety and performance. An overall increase in BG levels is expected as a result of decreased clinical intervention without increasing the risk of hypoglycemia. The performance of each controller was assessed by the following criteria: 
Virtual Patients
The target patients for these trials are critically ill, but in a relatively stable state. Seventeen (of 391) patients from the SPRINT cohort [7] met the following stability criteria:
• Stable hourly insulin requirement of ≤ 3U/hr of insulin, for at least 12 hours
• Stable nutrition rate of ≥ 60% of the calculated individual patient's goal rate, based on ACCP guidelines of 25kcal/kg/hr [24] • No acute renal failure
• Less than 1000ml of fluid given as intravenous boluses in the past 24 hours, indicating hemodynamic or circulatory stability and a stable interstitial volume.
• Resolving multiple organ failure based on a Sequential Organ Failure Assessment (SOFA) score < 6 [25] For safety and to limit Glargine bolus size in this initial study an additional criterion was:
• Maximum total insulin requirement of ≤ 48U, over the last 18 hours
These criteria define a set of patients who would be eligible for transfer to a HDU and a less intense AGC routine. The number (17) is low enough to create an initial protocol without excessive data, and other patients (of 391) might readily qualify. The total insulin dose criterion, chosen also for safety in planned clinical trials to limit dose, was a significant limiting factor for patient numbers. Table 3 presents the demographic details of the 17 patients. Table 4 shows the expected glycemic differences between Glargine dose sizes for the nominal 1.5x efficacy. The sum over 18 hours was selected due to the safety limits imposed on the Glargine dosage, and it showed a balance of %BG within the 4.0 -8.0 mmol/L band and %BG < 4.0 mmol/L, comparable to or better than SPRINT. While this choice reduced the number of nutrition changes required to maintain control using Glargine, it is evident that the fixed insulin dose requires greater nutrition adjustment compared to SPRINT, which used both in control. Based on these results, the final recommended SING controller comprises:
Results
• Glargine bolus size equal to the insulin administered over the previous 18 hours
• STAR recommended boluses used for the first and last 4 hours of the 24 hour period after Glargine has been administered, 1 hour treatments only during this period.
• During the period where Glargine is the only form of exogenous insulin, the 95 th percentile BG outcome is targeted to the high bound, all other times the 5 th percentile BG outcome is targeted to the low bound
• The upper tolerance on the upper BG target is 1 mmol/L
• Recommendations are made on the basis of a Glargine efficacy factor of 1.5 times
• Recommended dosage is rounded to the nearest 6U for clinical convenience Table 6 shows the final SING controller compared against SPRINT with varying efficacy levels. Figure 5 shows how BG varies for a representative patient for the 24-hour trial after an initial Glargine dose of 18U. The varying efficacy and the relatively linear relation between BG and insulin efficiency is observed as expected. Safety was not compromised. The median nutrition rate is 100% of goal rate regardless of efficacy. The results show that adequate control is achieved for the case where Glargine is no more potent than regular insulin and control is improved for higher potencies of Glargine. However, for a higher potency, the risk of mild hypoglycemia increases, but even at the maximum suspected potency (2.0x) there is still a significant improvement over the SPRINT protocol. The cumulative frequency of BG levels in Figure 6 clearly shows robustness with a good balance of safety and performance. There is a significant reduction in %BG < 4.4 mmol/L, and the relatively steep CDF slopes indicate the BG variability remains tightly controlled. The tight control achieved by the hourly STAR treatments has been proven to effectively control BG levels. Any unknown effects of Glargine will be compensated for with the model calculated insulin sensitivity. The small variance between the bands for varying efficacies in Figure 6 further indicates the robustness. Table 7 shows an example the results from the SING2 controller, where it is assumed the efficacy is known to be 1.5. SING2 offers improved performance over SPRINT with increased nutrition delivery, patient safety, and time in desired band. A significant reduction in clinical effort is observed with a 27% reduction in BG measurements, a 59% reduction in insulin boluses and a 67% decrease in the number of nutrition changes required. Hence, if the efficacy is known reliably, then significant clinical effort reductions can be obtained with good performance and safety. 
Discussion:
The simulation results for the SING controller and its variations show that it is a robust and safe initial protocol to investigate the safety and performance of Glargine in this cohort to reduce clinical effort and transition stable patients to subcutaneous delivery. A possible limitation of this study is the low number of virtual patients included in the cohort. SPRINT is used on a cohort from which such patients may come, but initial selection criteria may have been too strict. However, the cohort selected does fairly represent a combination of genders, medical conditions and age. A larger cohort of suitable patients, preferably in clinical testing, would enable a greater statistical validity of the results. However the results presented justify clinical testing to prove the concept.
The unknown efficacy of Glargine requires specific measures to reduce patient risk in these trials. Hence, a noticeable decrease in clinical effort is not observed for SING in these proposed trials. Even though there is a significant reduction in insulin boluses administered there is a significant increase in the number of nutrition changes required. However, the SING2 controller showed the potential reductions available if the efficacy is more reliably known. Highly patient-specific or variable efficacy discovered in the clinical trials designed here would thus create significant issues affecting the feasibility of using Glargine consistently in large cohorts of this type if reduction of effort is a major criterion.
In long term applications of Glargine over multiple days the periods of low insulin appearance in plasma during the Glargine's action will not be an issue if the kinetics and efficacy of Glargine is known. A protocol can be designed such that the Glargine profiles overlap to minimise periods of low insulin appearance. This outcome is achieved by administering smaller doses more frequently than 24 hours.
A limitation of this trial design is that the effect of Glargine build up over days is not observed. Build up can occur if Glargine is present for more than 24 hours [26] . Simulation results for a single isolated dose of Glargine suggested that the build up of Glargine in the interstitial insulin compartment was not a significant issue. However, this behaviour has been observed clinically and may still play a role. The increase in interstitial insulin concentration was 4.6% of the initial value after 24 hours and 2.5% after 26 hours. Hence, over several days, this issue may not be a major factor given measurement and other errors that also contribute to the overall variation in control.
Finally, the goal of the controller was to investigate the kinetics and dynamics of Glargine. It is likely this information will be achieved through analysis of model-based S I as the patient transitions to/from the Glargine only period. If (for example) SI shows a general increase or decrease over the Glargine period that is resolved with the reintroduction of IV insulin it would infer values for Glargine potency. During the Glargine only period nutrition rates may be modified.
Conclusions
This paper presents an investigation into the use of Glargine in AGC for low effort controllers. A robust clinical trial has been designed to safely investigate the efficacy and kinetics of Glargine, prior to developing a final protocol. If the results of this trial verify the efficacy and kinetics of Glargine in critically ill patients, a low effort controller can be implemented to extend AGC to the HDU. It remains for clinical testing to determine interand intra-patient variability, thus determining the overall potential for using Glargine in large cohorts of HDU patients and stable ICU patients.
Overall, the results demonstrate the concept and potential to justify pilot clinical trials.
Equally they clearly and safely highlight, in-silico, some issues with subcutaneous long acting insulin that may not otherwise have arisen until clinical testing. Hence, these outcomes should be prospectively tested.
